Reuters logo
BRIEF-Caladrius Biosciences awarded $12.2 mln grant from CIRM supporting Phase 2 trial of CLBS03
February 23, 2017 / 7:43 PM / in 8 months

BRIEF-Caladrius Biosciences awarded $12.2 mln grant from CIRM supporting Phase 2 trial of CLBS03

Feb 23 (Reuters) - Caladrius Biosciences Inc:

* Caladrius Biosciences awarded $12.2 million grant from CIRM in support of Phase 2 clinical trial of CLBS03 to treat type 1 diabetes

* Patients are currently being enrolled in second cohort of Phase 2 trial for CLBS03

* Interim analysis of Phase 2 trial for CLBS03’s early therapeutic effect expected by end of 2017

* Grant is to cover expenses including manufacturing, development based in California, and other costs for Phase 2 trial for CLBS03 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below